Skip to content

ANALYST REPORT — THG (Thonburi Healthcare Group PCL)

Spot ฿7.30 (2026-06-23 close). Sector: Services / Health Care Services. SET:THG ≠ NYSE:THG (Hanover Insurance) — Stocktwits data discarded per audit.

1. The business in 200 words

THG operates a mid-tier Thai private-hospital group anchored by Thonburi Hospital 1 and 2 in Bangkok, supplemented by branch hospitals (including Thonburi Trang, cited as a ฿500m/yr revenue contributor — Money & Banking, 9 Jul 2024) and the Jin Wellbeing elderly-care/wellness complex. Two diversification plays sit alongside the core: the Healthiva preventive-health/wellness brand (Money & Banking, 3 Jul 2024) and overseas hospital projects (Vietnam — The Investor, 10 Jun 2023; Myanmar — Bangkok Post, 16 Feb 2024). Three cancer centres were flagged as a ฿1.0–1.5bn capex programme (Bangkok Post, 22 May 2024).

Customer base is mainly fee-for-service Thai middle-class self-pay plus private insurance, with some medical tourism. Pricing power is structurally weaker than premium peers (BDMS, Bumrungrad) — THG sits below the BDMS/BH tier but competes with BCH and CHG for mass-affluent volume. Concentration risk: most EBITDA comes from two Bangkok hospitals. Post-2025, Ramkhamhaeng Hospital (RAM) is the controlling shareholder at 49.99%, fundamentally re-anchoring the business to Thailand's largest hospital-network operator.

2. 10-year financial trajectory

The data package does not contain a multi-year income statement, balance sheet or cash flow. SET financial and shareholder pages were either JS-shelled or returned 404 (per audit). What I can verify:

  • FY2025 revenue ฿9.10bn (−4.0% YoY); net income +฿96.2m vs −฿1.76bn FY2024 — a ~฿1.86bn swing, EPS ฿0.054 vs −฿2.08 (dossier).
  • Q3-2025 revenue ฿2.32bn (−8.3%), net income ฿5.12m, net margin 0.2% (dossier).
  • Share count grew ~111% through the 2025 RAM private placement (430.5m shares at ฿8.65) + rights offering at ฿5.00 (dossier, citing SET filing THG 21/2025).

Margin story (qualitative): FY24 loss → FY25 thin profit was driven by >฿300m/yr interest-cost reduction post-recap, not by operational recovery. Revenue actually declined. This is a balance-sheet turnaround, not yet an earnings-power turnaround.

Balance sheet: combined loans/debentures cited at ~฿9.6bn pre-deal; ฿6.28bn equity raise repaid a meaningful chunk. Exact post-recap net debt not verifiable in this package.

10-year price arc (from 60-session window + dossier): stock ranged to a ฿38.50 prior peak; now ฿7.30 — an ~81% drawdown from peak. Even within the visible 60-session window, the stock fell from ~฿9.35 (31 Mar 2026 high) to ฿7.25 (23 Jun 2026 low), a 23% fade in three months. No 10-year CAGR, vol, Sharpe or max DD is in the package — I will not invent them.

3. Sector & peer comparison

Thai private hospital sector tiering (dossier multiples; treat as indicative):

Peer P/E (cited) Position
BDMS ~18.5x, EV/EBITDA 11.3x, P/B 2.78 Premium, scale leader
BCH ~16.6x Mass + social-security
CHG ~16x FY26E Mass + social-security
THG n/m (earnings just turned) Mid-tier, single-network

THG's FY25 net margin ~1.1% (and Q3-25 0.2%) is roughly 10–15 percentage points below peers' double-digit net margins cited in the dossier. The gap is the entire investment debate: does RAM control close it?

Sector tailwinds: Thai ageing demographic (median age rising; VOA 2018 piece on elderly-expat developers still directionally relevant), medical tourism recovery post-COVID, regulatory regime stable. Sector headwinds noted in package: a "Crisis of Confidence" piece (Nation Thailand, 28 Dec 2025) explicitly ties Thai corporate scandals — Boon being one — to SET multi-year lows; sector sentiment is fragile.

4. Capital allocation track record

The 10-year track record under founder Boon Vanasin is poor and now compromised: - Pre-2024 capex was aggressive and diversified (Vietnam, Myanmar, three cancer centres, ฿5bn 2023–25 plan per Bangkok Post, 17 Mar 2023; Healthiva brand launch). - Leverage funded that growth and proved unaffordable — hence FY24 ฿1.76bn loss and the need for a forced recap. - Dividend history not in package — cannot verify payout discipline. - The founder is a fugitive in a ฿16.1bn fraud case (Thai PBS World, 30 Nov 2024; Bangkok Post, 14 Dec 2024). Minority-shareholder alignment under prior management cannot be assumed.

Under RAM control (post-Apr 2025): new independent directors (Sam Tanskul eff. 20 Feb 2025; Paradorn Leosakul eff. 31 Mar 2025); RAM took a whitewash waiver — explicitly stating no full takeover intent. This is a meaningful governance reset, but RAM's capital-allocation discipline at THG is unproven yet (one year of control). Form 59-2 insider-transaction detail not in the package.

5. Macro sensitivities (rough quantification)

THG is less macro-geared than BANPU/PTT-type names. The relevant sensitivities, in order:

  1. Thai interest rates / BOT policy — directly mechanical post-recap. The dossier cites ">฿300m/yr interest savings" from the recap. A 100bp rate cut on residual ฿3–4bn net debt would add roughly ฿30–40m to PBT — material against a ฿96m FY25 net income base. Rough estimate, unverified line items.
  2. THB/USD — medical tourism revenue mix unclear from package, but a weaker baht typically helps inbound patient volumes; not quantifiable here.
  3. Thai consumer confidence / SET sentiment — Nation Thailand (28 Dec 2025) explicitly cites scandal-driven confidence crisis. Self-pay healthcare demand is income-elastic at THG's tier.
  4. Wage inflation (nurses/doctors) — doctor-shortage is a sector issue (THG-Assumption scheme, Bangkok Post, 19 Jan 2024). Pressures opex.
  5. Regional expansion FX — Vietnam/Myanmar exposure exists but size is undisclosed.

6. Recent news flow & narrative (last 12 months)

The narrative in the package is dominated by two events:

  1. Boon scandal (Sept 2024 → ongoing): fled Thailand, arrest warrants 22 Nov 2024, ฿16.1bn estimated damages, AG charges against Boon + 12 others, family detained, asset-seizure moves (SCMP, 5 Jan 2025; Bangkok Post, 25–26 Nov 2024; Thai PBS World, 30 Nov 2024). Company has formally denied any role in the fraud (Bangkok Post, 26 Nov 2024).
  2. RAM takeover & recap (Feb–Apr 2025): 24.59% → 49.99%, ฿6.28bn raised, debt repaid, board reshuffled.

Operational items remain thin: Trang Hospital scale-up (Jul 2024), Healthiva launch (Jul 2024), Vietnam/Myanmar expansion (2023–24), three cancer centres (May 2024). These are legacy strategy items announced under prior management — RAM's actual operational plan is not disclosed in the package.

The market verdict in the 60-session window is clear: stock down from ฿9.35 to ฿7.30 (−22%) since end-March 2026, with notable distribution days on 13 May (−4.5%, 4.2m vol) and 19 Jun (−3.3%, 6.0m vol). Post-recap optimism is bleeding out.

7. 2-year forecast

Caveat: No analyst consensus, no company guidance, no quarterly/segment detail in the package. The forecast below is built off the only three verified anchors (FY25 revenue ฿9.10bn, net income ฿96m; >฿300m interest savings; peer multiples).

FY+1 (FY2026E)

  • Revenue: ฿9.0–9.4bn (flat-to-low-single-digit). Trang ramp + Healthiva offsetting Bangkok softness; no evidence yet of RAM-driven volume uplift.
  • EBITDA: not estimable — no historical EBITDA line in package.
  • Net income: ฿250–400m — full year of recap savings (>฿300m vs partial-year benefit in FY25) plus modest opex discipline. EPS ~฿0.14–0.22 on ~1.79bn shares.
  • DPS: ฿0.00–0.05 — dividend resumption plausible but unconfirmed; payout history not in package.

FY+2 (FY2027E)

  • Revenue: ฿9.4–10.2bn (+4–8%) — assumes some RAM cross-referral synergy and cancer-centre ramp.
  • Net income: ฿400–700m — base case assumes margins to ~4–6%, still well below BDMS/BCH double-digit. EPS ~฿0.22–0.39.
  • DPS: ฿0.05–0.15 — assumes ~30–40% payout once profits clear ฿0.20 EPS.

Fair value range

At FY27E EPS ฿0.30 (midpoint) × 12–16x P/E (discount to BCH/CHG at 16x for execution risk + Boon legal overhang): ฿3.6–4.8 base, ฿5–7 if market gives RAM full benefit of the doubt.

Pulling in book-value support and the ฿8.65 RAM placement price as a soft floor reference, my two-year fair-value range is ฿6–9, midpoint ฿7.5.

The ฿30 owner-thesis target requires ~฿3.0–3.5bn net profit at peer multiples — roughly 30–40x FY25 net income. That is a 5+ year story under flawless execution, not a 2-year case.

8. Key risks (ranked)

  1. Boon legal contagion — civil clawback claims against THG assets, even if company denies involvement (฿16.1bn damages pool is ~2.5x THG's market cap at ฿7.30).
  2. Margin disappointment — if RAM synergy fails to deliver double-digit net margins by FY27, the re-rating thesis dies.
  3. Equity overhang — RAM whitewash limits forced selling, but residual Vanasin ~4.2% stake and possible court-ordered disposals could pressure the float.
  4. Sector multiple compression — Nation Thailand (Dec 2025) flags SET at seven-year lows on scandal fatigue; hospital sector is not immune.
  5. Capex relapse — three cancer centres + overseas expansion could reabsorb the recap benefit if RAM doesn't impose discipline.

9. Rating: HOLD

Fair value ฿6–9, midpoint ฿7.5 vs spot ฿7.30 — essentially fairly priced.

The bull case (RAM cleans this up, margins triple, multiple re-rates) is real but speculative; the bear case (Boon legal contagion, margin stagnation) is equally live. The recap is done, the easy money has been made (FY25 swing to profit), and the next leg requires operational evidence that does not yet exist in the public record. I'd upgrade to BUY on either (a) a credible RAM operational plan with margin guidance, or (b) clean legal resolution of the Boon case. I'd downgrade to SELL on any sign of Boon-related claims attaching to THG corporate assets.

The owner thesis ("฿30 in 2–5 years") is not supported by the data in this package. ฿30 implies ~4x and needs ~30x earnings growth at peer multiples — a 5+ year flawless-execution scenario, not a base case. A defensible bull target is low-to-mid teens by FY28–29 on demonstrated synergy.

Sources cited in-line: Bangkok Post; SCMP; Thai PBS World; Money & Banking; Nation Thailand; The Investor; SET filing THG 21/2025 (via dossier); yfinance OHLCV 2026-03-26→2026-06-23. Items flagged "not in package" must not be treated as fact.